Preclinical characterisation of the GM-CSF receptor as a therapeutic target in rheumatoid arthritis

Annals of the Rheumatic Diseases

Volumn 74, Issue 10, 2015, Pages 1924-1930

  Greven, D E A ^a   Cohen, E S ^b   Gerlag, D M ^a,c   Campbell, J ^b   Woods, J ^b   Davis, N ^b   Van Nieuwenhuijze, A ^d   Lewis, A ^b   Heasmen, S ^b   McCourt, M ^b   Corkill, D ^b   Dodd, A ^b   Elvin, J ^b   Statache, G ^a   Wicks, I P ^d   Anderson, I K ^b   Nash, A ^e   Sleeman, M A ^b   Tak, P P ^a,c,f  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b MEDIMMUNE LTD   (United Kingdom)

^c GLAXOSMITHKLINE   (United Kingdom)

^d WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^e CSL LIMITED   (Australia)

^f UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CAM 3003; CD163 ANTIGEN; CD68 ANTIGEN; COLLAGEN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR RECEPTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR RECEPTOR ANTIBODY; MAVRILIMUMAB; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISOLONE; RECEPTOR ANTIBODY; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; UNCLASSIFIED DRUG; ANTIRHEUMATIC AGENT; CAM-3003; MONOCLONAL ANTIBODY;

ADULT; ANIMAL TISSUE; ARTICLE; BAGG ALBINO MOUSE; CD-1 MOUSE; CLINICAL ARTICLE; CONTROLLED STUDY; DBA 1 MOUSE; DRUG TARGETING; FEMALE; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; INSTITUTE FOR CANCER RESEARCH MOUSE; JOINT BIOPSY; MACROPHAGE; MALE; MONOCYTE; MOUSE; NEUTROPHIL; NONHUMAN; OSTEOARTHRITIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSORIATIC ARTHRITIS; RHEUMATOID ARTHRITIS; SYNOVIUM; AGED; ANIMAL; ANTAGONISTS AND INHIBITORS; ARTHRITIS, EXPERIMENTAL; BLOOD; CASE CONTROL STUDY; DBA MOUSE; DOSE RESPONSE; DRUG SCREENING; IMMUNOLOGY; METABOLISM; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; PROCEDURES;

ADULT; AGED; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, PSORIATIC; ARTHRITIS, RHEUMATOID; CASE-CONTROL STUDIES; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; DRUG EVALUATION, PRECLINICAL; FEMALE; HUMANS; MALE; MICE, INBRED BALB C; MICE, INBRED DBA; MIDDLE AGED; MOLECULAR TARGETED THERAPY; OSTEOARTHRITIS; RECEPTORS, GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; SYNOVIAL MEMBRANE;

EID: 84942847175     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2014-205234     Document Type: Article

References (37)

1. Hamilton JA, Tak PP. The dynamics of macrophage lineage populations in inflammatory and autoimmune diseases. Arthritis Rheum 2009; 60: 1210-21.
2. van Nieuwenhuijze A, Koenders M, Roeleveld D, et al. GM-CSF as a therapeutic target in inflammatory diseases. Mol Immunol 2013; 56: 675-82.
3. Cornish AL, Campbell IK, McKenzie BS, et al. G-CSF and GM-CSF as therapeutic targets in rheumatoid arthritis. Nat Rev Rheumatol 2009; 5: 554-9.
4. Hamilton JA Colony-stimulating factors in inflammation and autoimmunity. Nat Rev Immunol 2008; 8: 533-44.
5. Hamilton JA, Anderson GP. GM-CSF Biology. Growth Factors 2004; 22: 225-31.
6. de Vries EG, Willemse PH, Biesma B, et al. Flare-up of rheumatoid arthritis during GM-CSF treatment after chemotherapy. Lancet 1991; 338: 517-18.
7. Hazenberg BP, Van Leeuwen MA, Van Rijswijk MH, et al. Correction of granulocytopenia in Felty's syndrome by granulocyte-macrophage colony-stimulating factor. Simultaneous induction of interleukin-6 release and flare-up of the arthritis. Blood 1989; 74: 2769-70.
8. Pereira J, Velloso ED, Loterio HA, et al. Long-term remission of neutropenia in Felty's syndrome after a short GM-CSF treatment. Acta Haematol 1994; 92: 154-6.
9. Hercus TR, Broughton SE, Ekert PG, et al. The GM-CSF receptor family: mechanism of activation and implications for disease. Growth Factors 2012; 30: 63-75.
10. Alvaro-Gracia JM, Zvaifler NJ, Brown CB, et al. Cytokines in chronic inflammatory arthritis. VI. Analysis of the synovial cells involved in granulocyte-macrophage colony-stimulating factor production and gene expression in rheumatoid arthritis and its regulation by IL-1 and tumor necrosis factor-alpha. J Immunol 1991; 146: 3365-71.
11. Wright HL, Bucknall RC, Moots RJ, et al. Analysis of SF and plasma cytokines provides insights into the mechanisms of inflammatory arthritis and may predict response to therapy. Rheumatology (Oxford) 2012; 51: 451-9.
12. Berenbaum F, Rajzbaum G, Amor B, et al. Evidence for GM-CSF receptor expression in synovial tissue. An analysis by semi-quantitative polymerase chain reaction on rheumatoid arthritis and osteoarthritis synovial biopsies. Eur Cytokine Netw 1994; 5: 43-6.
13. Behrens F, Tak PP, Ostergaard M, et al. MOR103, a human monoclonal antibody to granulocyte-macrophage colony-stimulating factor, in the treatment of patients with moderate rheumatoid arthritis: results of a phase Ib/IIa randomised, double-blind, placebo-controlled, dose-escalation trial. Ann Rheum Dis 2014; 74: 1058-64.
14. Burmester GR, Feist E, Sleeman MA, et al. Mavrilimumab, a human monoclonal antibody targeting GM-CSF receptor-alpha, in subjects with rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase I, first-in-human study. Ann Rheum Dis 2011; 70: 1542-9.
15. Burmester GR, Weinblatt ME, McInnes IB, et al. Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritis. Ann Rheum Dis 2013; 72: 1445-52.
16. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24.
17. Taylor W, Gladman D, Helliwell P, et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006; 54: 2665-73.
18. van de Sande MG, Gerlag DM, Lodde BM, et al. Evaluating antirheumatic treatments using synovial biopsy: a recommendation for standardisation to be used in clinical trials. Ann Rheum Dis 2011; 70: 423-7.
19. Tak PP, van der Lubbe PA, Cauli A, et al. Reduction of synovial inflammation after anti-CD4 monoclonal antibody treatment in early rheumatoid arthritis. Arthritis Rheum 1995; 38: 1457-65.
20. Kraan MC, Haringman JJ, Ahern MJ, et al. Quantification of the cell infiltrate in synovial tissue by digital image analysis. Rheumatology (Oxford) 2000; 39: 43-9.
21. Kraan MC, Reece RJ, Barg EC, et al. Modulation of inflammation and metalloproteinase expression in synovial tissue by leflunomide and methotrexate in patients with active rheumatoid arthritis. Findings in a prospective, randomized, double-blind, parallel-design clinical trial in thirty-nine patients at two centers. Arthritis Rheum 2000; 43: 1820-30.
22. Vergunst CE, van de Sande MG, Lebre MC, et al. The role of chemokines in rheumatoid arthritis and osteoarthritis. Scand J Rheumatol 2005; 34: 415-25.
23. Rosloniec EF, Cremer M, Kang AH, et al. Collagen-induced arthritis. Curr Protoc Immunol 2010; Chapter 15: Unit 15.5.1-25.
24. Field M, Clinton L. Expression of GM-CSF receptor in rheumatoid arthritis. Lancet 1993; 342: 1244.
25. Tak PP, Smeets TJ, Daha MR, et al. Analysis of the synovial cell infiltrate in early rheumatoid synovial tissue in relation to local disease activity. Arthritis Rheum 1997; 40: 217-25.
26. Haringman JJ, Gerlag DM, Zwinderman AH, et al. Synovial tissue macrophages: a sensitive biomarker for response to treatment in patients with rheumatoid arthritis. Ann Rheum Dis 2005; 64: 834-8.
27. Wijbrandts CA, Vergunst CE, Haringman JJ, et al. Absence of changes in the number of synovial sublining macrophages after ineffective treatment for rheumatoid arthritis: implications for use of synovial sublining macrophages as a biomarker. Arthritis Rheum 2007; 56: 3869-71.
28. Gerlag DM, Haringman JJ, Smeets TJ, et al. Effects of oral prednisolone on biomarkers in synovial tissue and clinical improvement in rheumatoid arthritis. Arthritis Rheum 2004; 50: 3783-91.
29. van Kuijk AW, Reinders-Blankert P, Smeets TJ, et al. Detailed analysis of the cell infiltrate and the expression of mediators of synovial inflammation and joint destruction in the synovium of patients with psoriatic arthritis: implications for treatment. Ann Rheum Dis 2006; 65: 1551-7.
30. Hovgaard D, Schifter S, Rabol A, et al. In vivo kinetics of 111indium-labelled autologous granulocytes following i.v. administration of granulocyte-macrophage colony-stimulating factor (GM-CSF). Eur J Haematol 1992; 48: 202-7.
31. Yong KL, Linch DC. Granulocyte-macrophage-colony-stimulating factor differentially regulates neutrophil migration across IL-1-activated and nonactivated human endothelium. J Immunol 1993; 150: 2449-56.
32. Minter RR, Cohen ES, Wang B, et al. Protein engineering and preclinical development of a GM-CSF receptor antibody for the treatment of rheumatoid arthritis. Br J Pharmacol 2013; 168(I): 200-11.
33. Yong KL, Rowles PM, Patterson KG, et al. Granulocyte-macrophage colony-stimulating factor induces neutrophil adhesion to pulmonary vascular endothelium in vivo: role of beta 2 integrins. Blood 1992; 80: 1565-75.
34. Khajah M, Millen B, Cara DC, et al. Granulocyte-macrophage colony-stimulating factor (GM-CSF): a chemoattractive agent for murine leukocytes in vivo. J Leukoc Biol 2011; 89: 945-53.
35. Cook AD, Braine EL, Campbell IK, et al. Blockade of collagen-induced arthritis post-onset by antibody to granulocyte-macrophage colony-stimulating factor (GM-CSF): requirement for GM-CSF in the effector phase of disease. Arthritis Res 2001; 3: 293-8.
36. Cook AD, Turner AL, Braine EL, et al. Regulation of systemic and local myeloid cell subpopulations by bone marrow cell-derived granulocyte-macrophage colony-stimulating factor in experimental inflammatory arthritis. Arthritis Rheum 2011; 63: 2340-51.
37. Nishiya K, Hisakawa N, Hosokawa T, et al. Enlarged spleen detected by abdominal ultrasonography in patients with RA. Ann Rheum Dis 2000; 59: 751-2.